A Phase IIII Study of AL8326 in Small Cell Lung Cancer

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.

Timeline

Start

2023-10-26

Primary completion

2028-07

Completion

2029-07

Drugs

Indications